Introduction
Peripheral vascular disease (PVD) and myocardial ischemia persist in part due to the body's inability to spontaneously revascularize through the processes of angiogenesis and vasculogenesis. Therapeutic attempts to treat ischemia with angiogenic factors have been largely ineffective (Collinson and Donnelly, 2004) . Cell-based therapies have been initiated with the hypothesis that cells may provide a more effective mixture of secreted factors to stimulate revascularization. Previously our laboratory and others have demonstrated that freshly isolated adipose-derived regenerative and stem cells can induce new vascular network formation through the reassembly of endothelial cells at the site of implantation (Koh et al., 2011; Nunes et al., 2013) . The formation of new patent vessels has been shown to involve both denovo vessel formation from existing vessels (angiogenesis) and the formation of new vessels through self-assembly of transplanted cells (vasculogenesis) . Implanted adipose-derived cells progress through distinct phases of neovascularization to eventually form a complete vascular network: vasculogenesis/angiogenesis, vascular remodeling and pruning, and finally, vascular maturation (LeBlanc et al., 2012; Nunes et al., 2010) .
The majority of studies on neovascularization potential of cells of mesenchymal origin have used bone marrow-derived sources (BMSCs). More recently, adipose-derived stromal cells (ADSCs) have been shown to possess similar pro-angiogenic capabilities. ADSCs can form vascular networks by direct interactions with endothelial cells through cell incorporation (Merfeld-Clauss et al., 2010) , but also through extensive paracrine mechanisms to modulate the process of angiogenesis (Rehman et al., 2004; Yang et al., 2013) . Comparatively, human ADSCs have been shown to exhibit superior therapeutic potential when compared to human BMSCs in a mouse hindlimb ischemia model (Kim et al., 2007) . Even though clinical presentations of ischemia so often occur in states of advanced age, there have been surprisingly few studies utilizing adipose-derived cells from older individuals to determine age-related potential for vascular therapy. The neovascularization potential of the adipose-derived regenerative and stem cell population from aged donors may be diminished.
Advanced age has been reported to be associated with poor wound healing responses suggesting that an age-related defect exists in the cell-dependent mechanisms that regulate neovascularization. Whether the age of the donor renders these cells ineffective in overall neovascularization potential or a deficit in one of the phase components remains unknown, but is important to ascertain if an autologous cell-based approach is to be utilized for patients with vascular ischemia. Numerous studies have suggested that adipose tissue from older humans and animals demonstrates cellular deficiencies, such as lower proliferation rates and greater susceptibility to apoptosis (Schipper et al., 2008) . The general consensus is mesenchymal stem cells (MSCs) and progenitor cells lose proliferative and differentiation capacity with advancing age (Stolzing et al., 2008) , but this loss of cell function hasn't been investigated in the heterogeneous adipose-derived stromal vascular fraction (SVF) cell populations.
The SVF represents a heterogeneous cell population that resides within adipose tissue and is comprised of endothelial cells, smooth muscle cells, macrophages, blood cells and mesenchymal stem cells (Zimmerlin et al., 2010) . Adipose-derived cells have recently become the focus of numerous efforts designed to mitigate ischemia and heart failure in animal models (Mazo et al., 2008; Miyahara et al., 2006; Wang et al., 2009; Zhang et al., 2007) and clinical applications (Gir et al., 2012) . Adipose tissue represents an attractive cell source for regenerative medicine due to the ease of isolation, abundance, and the ability of some cells to differentiate into various mesodermal cell lineages (Lin et al., 2008) . The purpose of this study was to directly assess the age-related neovascularization potential of isolated SVF cells in an in vivo model with further in vitro characterization. Our overall hypothesis was that SVF isolated from aged rats (oSVF) would display decreased vasculogenic function in vivo compared to cells from young rats (ySVF), and that this would be decreased due to impaired capillary-like tube formation. Contrary to our hypothesis, we provide evidence here that the vasculogenic potential of SVF appears to be maintained with advancing age, but network maturation is impaired in oSVF in vivo. We believe greater pruning and/or poor adaptation to the initiation of perfusion and inosculation results in fewer cells and vessels maintained when oSVF cells are used.
Materials and methods
All animal surgeries were performed in accordance with protocols approved by the University of Louisville Institutional Animal Care and Use Committee and the NIH Guide for the Care and Use of Laboratory Animals (9th ed., 2011).
SVF Isolation
Young (4 months) and old (24 months) male and female Fischer-344 rats (Harlan Laboratories, Indianapolis, IN, USA and National Institute on Aging, Bethesda, MA, USA, respectively) were anesthetized (40-80 mg/kg ketamine and 5-10 mg/kg xylazine), epididymal or ovarian fat was excised, and the rat was euthanized by removal of the heart. The fat was washed in 0.1% bovine serum albumin in phosphatebuffered saline (BSA-PBS), finely minced, and enzymatically digested with 2 mg/mL type I collagenase (type I collagenase, Worthington Biochemical Company, NJ) for 40 min at 37°C. After digestion, the tissuecollagenase mixture was centrifuged, buoyant adipocytes were removed, and the top two layers of the cell pellet were retrieved to obtain the SVF.
Construct formation and implant
As previously described, young rat SVF (ySVF) or old rat SVF (oSVF) cells were used immediately after isolation for construct implants by combining with BD Biosciences rat-tail type I collagen (3.0 × 10 6 cells/mL) and 4 × DMEM to form three-dimensional (3D)
constructs (Nunes et al., 2011) . Briefly, two constructs per mouse were subcutaneously implanted into the dorsal flank of 6 week old immunodeficient Rag1 mice (B6;129S7-Rag1 tm1Mom /J, Jackson Laboratories, Bar Harbor, MA, USA). At four weeks post-implant, the mice were perfused with 250 μL of 2 mg/mL dextran-rhodamine (Dex +, 2,000,000 MW, Invitrogen) for 15 min before construct explant to delineate perfused vessels. One construct from each mouse was designated for confocal microscopy imaging and the other for immunohistochemistry (IHC). Following explant, IHC constructs were fixed in paraformaldehyde while those for confocal imaging were fixed, permeabilized, and stained with 0.1 mg/mL fluorescein-conjugated Griffonia simplicifolia I (GS-1) lectin overnight (Vector Labs) to label all vascular elements, and confocal laser microscopy was performed (Olympus model BX61WI; Olympus America Inc, Central Valley, PA).
Vessel perfusion and vessel density analysis
To estimate the vascular volume index fraction (VVIF), individual slices of confocal image stacks obtained at 20 × magnification were processed as previously reported (Nunes et al., 2010) . The percent perfusion of vasculature is calculated by dividing the volume of perfused vessels by the entire vessel volume (Dex+ VVIF / GS-1+ VVIF ), averaged from three image stacks throughout each construct. The absolute number of Dex+ and GS-1+ vessels was calculated manually by using the counting tool in Adobe® Photoshop (Adobe Systems Incorporated, San Jose, CA). Results are presented in multiple aspects: as the number of GS-1+ and Dex+ vessels per mm 2 , percent perfused vessel volume relative to total, and vessel diameter distribution for ySVF or oSVF constructs. Vessel diameter distribution was calculated by measuring diameters of all vessels present in a 3D construct (ySVF or oSVF) and binning them in 5 μm increments.
LIVE/DEAD assay
The LIVE/DEAD Viability/Cytotoxicity Kit (Life Technologies) was used per manufacturer's instructions to determine viability after cell isolation. 3 images/sample were taken with a fluorescent microscope (Olympus model IX51; Olympus America Inc, Central Valley, PA) and averaged to determine percent viability ([# live cells / # dead cells] * 100).
RNA and RT-qPCR for angiogenic markers
The RT2 Profiler PCR Array for Rat Growth Factors (Qiagen) was used to evaluate 84 genes related to angiogenic growth factors. RNA was purified from freshly isolated ySVF or oSVF cultured to confluence on tissue culture flasks (n = 3/group). Total RNA was isolated using the RNeasy minikit (Qiagen). cDNA was prepared using RT2 First Strand Kit (Qiagen). Using an iCycler iQ (BioRad), baseline and threshold were set according to manufacturer's instruction (Qiagen). Only arrays that passed the PCR Array Reproducibility, RT Efficiency and Genomic DNA contamination tests were included in the analysis. Data was analyzed using the RT2 Profiler PCR Array Data Analysis v3.5 (SABiosciences). Average Delta(Ct) was calculated by the following equation: (Ct(gene of interest) − Avg Ct(housekeeping genes)). Fold-change (2 (−Delta Delta Ct) ) is the normalized gene expression (2 (− Delta Ct) ) in the test sample (oSVF) divided the normalized gene expression (2 (−Delta Ct) ) in the control (ySVF). Fold regulation is equal to fold change. To analyze how well grouped the oSVF gene fold changes relative to ySVF were, standard error bars were calculated using the multi-plot functionality of the RT2 Profiler PCR Array Data Analysis v3.5 (SABiosciences). Fold change for specified genes was plotted and a confidence interval or error bar was generated using the following equation: σFC = FC * ln2 * sqrt(σ x 2 / n x + σ y 2 / n y ) where FC correlates to the fold change, σ represents the standard deviation, n reflects the sample size, and x and y are the oSVF and ySVF sample values, respectively. p values were generated using Student's t-test statistical analysis with p b 0.05 being considered significant.
Flow cytometry
Cell surface markers were characterized in the SVF cell population by flow cytometry using a LSR II flow cytometer (BD Biosciences). The SVF cells were freshly isolated, filtered through a 100 μm screen to remove large debris, and cell markers for VEGFR2, c-Kit (Abcam), CD11b (eBioscience), CD31 (BD Biosciences), CXCR2 (R&D Systems), CD47, CD34, and PDGFR (Santa Cruz) were used. Secondary antibodies, when appropriate, were used (goat-anti-rabbit and Streptavidin, Abcam). Antibody dilutions were optimized for each marker. Single color tubes were used to generate compensation controls. Tubes containing unstained SVF and additional tubes treated with appropriate isotype controls were used in setting discrimination gates. Positive populations were identified by quadrant gating dot plots using FlowJo 7.6.2 analysis software (Tree Star Inc, Ashland, OR).
Protein isolation and western blot
Total protein extract of ySVF, oSVF, and two-and four-week construct explants with ySVF or oSVF was quantified using a Bradford Protein Assay (Bio-Rad). Protein isolated from rat spleen tissue served as a positive control for Thbs-1 (Kaur et al., 2013) . Protein samples were combined with non-reducing sample buffer (62.5 mM Tris-HCl, 25% Glycerol, 1% Bromophenol Blue; used as 10×) and ran on 4-20% MiniProtean® TGX™ Gels (BioRad 456-1094) at 100 V under non-reducing conditions (running buffer: 25 mM Tris, 192 mM Glycine). Electrophoresis was followed by transfer to a PVDF membrane (Millipore IPFL00010) at 40 V at 4°C. Blots were blocked with 5% dry milk for 1 h at RT, probed with non-reduced anti-thrombospondin-1 (α-Thbs-1) antibody (1:500, 2 μg/mL, Tsp Ab-3(C6.7), Thermo Scientific) overnight at 4°C and anti-beta-actin (1:1000, Santa Cruz) for loading control. Fluorescently tagged goat-anti-mouse IgG Dylight 488 antibody (2 μg/mL, Vector Labs) for 2 h at RT was used to detect bound primary antibodies. Densitometry was performed using ImageJ software (NIH). Results were normalized to loading control first, and then to ySVF Thbs-1 levels for reporting.
TUNEL staining
Constructs were explanted, processed through paraffin and 5 μm sections obtained and mounted on slides. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using the DeadEnd Fluorometric TUNEL system (Promega G3250) with the addition of counterstaining with 4′,6-diamidino-2-phenylindole (DAPI). Three images of each stained construct were obtained with an epifluorescent microscope (Olympus IX51). Images were overlaid (TUNEL + and DAPI +) and double positive cells and total cells were counted using cellSens Standard (Olympus America Inc, Central Valley, PA).
Vasculogenic assessment and thrombospondin-blocking effect on in vivo construct development
To evaluate the role of thrombospondin-1 in neovascularization, we performed antibody blocking experiments in oSVF constructs and explanted after two weeks. oSVF constructs were processed as in Section 2.2 with the addition of an α-Thbs-1 antibody according to manufacturer's recommended concentration (0.06 M, Tsp Ab-3(C6.7), Thermo Scientific) or a control anti-mouse IgG1 antibody (Santa Cruz) prior to polymerization. The conditions tested were oSVF plus control IgG (oSVF + IgG) and oSVF plus α-Thbs-1 antibody (oSVF + α-Thbs-1). Constructs were analyzed and results reported the same as the four-week constructs described in Section 2.2.
Statistical analysis
Data is expressed as mean values ± SE except for flow cytometry data presented as mean values ± SD. Comparison of two homoscedastic groups was done with unpaired two-tailed Student's t-test. Statistical significance was set at p b 0.05. Each N corresponds to separate SVF isolations from separate rats.
Results

Age of SVF donor determines extent of functional vascular network assembly
To determine whether the age of donor SVF cells effects neovascularization, in vivo collagen constructs containing either ySVF or oSVF were implanted subcutaneously into mice and explanted after four weeks. Vessel formation was examined by counting perfused and total vessels (Fig. 1A) . At four weeks, a decrease in the mean total vessels in oSVF constructs (35.5 ± 3.0 vessels/mm 2 ) compared to ySVF constructs (55.4 ± 7.4 vessels/mm 2 ) was observed (Fig. 1B) . A decrease in the mean count of perfused vessels for oSVF constructs (16.9 ± 2.0 vessels/mm 2 , N = 11) compared to the mean count for ySVF constructs (29.9 ± 6.1 vessels/mm 2 , N = 13) was also observed (Fig. 1C) . Network function was analyzed by volume-calculated VVIF percentage where the volume of perfused vessels was divided by the volume of total vessels. ySVF construct vessels showed a higher percent of perfused volume than oSVF (ySVF = 46.9 ± 8.17%, N = 11; oSVF = 26.1 ± 2.82%, N = 12; Fig. 1D ). Network architecture and vascular maturation were assessed by vessel diameter frequency distribution at four weeks in ySVF and oSVF (Fig. 1E ). These distributions show that ySVF constructs contain larger, more mature vessels compared to constructs with oSVF.
SVF characterization prior to implant
To identify possible reasons for the differences in vascular network formation observed in the in vivo constructs, we considered that cell viability within the oSVF was reduced upon initial implant. However, LIVE/ DEAD assay revealed similar viability between ySVF and oSVF cell isolates (ySVF = 81.6 ± 3.9%, N = 9, oSVF = 87.8 ± 4.9%, N = 15; Fig. 2A ).
Another possible reason may be that expression of angiogenesisrelated genes in SVF isolates from young and old donors may differ. Angiogenic growth factor gene array was performed on SVF isolated from each age group (n = 3 arrays/group, each donor SVF = 1 array). Surprisingly, SVF from old rats exhibited an increase in expression of many common angiogenic growth factors, including VEGF (2.17-fold), HGF (2.8-fold), and PDGFβ (4.04-fold) (Table 1 ), but none of these reached statistical significance. Of note, oSVF exhibited increased fold expression of thrombospondin-1 (Thbs-1, 6.72-fold), a matricellular protein associated with potent inhibition of angiogenesis and migration (Table 1 ). All genes analyzed are listed in Supplementary Table 1. Fig. 1 . Reduced neovascularization potential of SVF from old donors. Collagen constructs containing freshly isolated SVF from young or old donors (young n = 13, old n = 11) were implanted in Rag1 mice for four weeks. Prior to explant, perfused vessels were stained with dextran-rhodamine and post-explant all vessels were stained with GS-1-fluorescein. Constructs were imaged by confocal microscopy (A). SVF constructs from old donors showed a reduction in total and perfused vessel density (B, C). A reduction in the percent of perfused vessel volume (volume perfused vessels / volume total vessels × 100) was observed in networks formed by old SVF (D). Analysis of the size distribution of vessels showed a shift towards smaller diameters in old SVF constructs at four weeks (young n = 7, old n = 8) (E). Scale bars are 100 μm, *p b 0.05. Fig. 2 . Donor age effects expression of angiogenesis-related factors in SVF. LIVE/DEAD assay (young n = 9, old n = 15) showed no age related difference in viability of freshly isolated SVF (A). Flow cytometry of freshly isolated SVF (n = 3 per group) revealed age-dependent expression of the cell surface receptors VEGFR2, CD47, and CXCR2, but not CD11b, CD31, CD34, cKit, or PDGFR (B). Western blot analysis showed increased expression of the anti-angiogenic matricellular protein thrombospondin-1 in old SVF (n = 7 both groups). Representative blot and quantification are shown (E). *p b 0.05.
We characterized SVF by evaluating the proportions of cells positive for select cell surface markers associated with angiogenesis, stem cell differentiation, and inflammation markers. SVF cell isolates from young and old animals (n ≥ 3 per group) were stained for VEGFR2, PDGFR (angiogenesis), and CD47 (angiogenesis, receptor for Thbs-1), c-Kit and CD34 (stem cell), CD11b (inflammation), CD31 (endothelial cell marker), and CXCR2 (inflammation, receptor for CXCL5). The SVF cell isolates exhibited an age-related difference in the number of cells positive for VEGFR2+ (ySVF = 18.7 ± 3.4%, oSVF = 10.0 ± 1.1%) and CXCR2+ (ySVF = 0.6 ± 0.2%, oSVF = 2.2 ± 0.6%). In addition, a bright sub-population of CD47+ cells was reduced in old compared to young (ySVF = 82.6 ± 1.9%, oSVF = 69.3 ± 2.8%; Fig. 2B ). However, this change was relatively small. Representative dot plots for markers exhibiting significant age-related differences are shown in Supplemental Fig. 2 . No other investigated cell markers exhibited age related differences (Fig. 2B) .
Since Thbs-1 is such a potent inhibitor of angiogenesis and has been shown to limit recovery of ischemic tissue (Isenberg et al., 2007) , and because of the corresponding age-related differences in Thbs-1 gene expression and CD47 cell marker expression, we decided to further explore Thbs-1 in the present study. Fig. 2C shows an age-dependent increase in Thbs-1 protein expression for oSVF compared to ySVF. The oSVF had nearly double Thbs-1 expression at 191 ± 28.9% when normalized to the ySVF values (100 ± 8.2%, N = 7 per group; Fig. 2C ). This data shows a clear age-dependent change in the expression of Thbs-1 in SVF at the onset of construct formation and may be responsible for the decrease in neovascularization seen in the oSVF implants. Thbs-1 was undetectable in both ySVF and oSVF two-and four-week explanted constructs (data not shown).
Time-dependent rate of apoptosis in implanted vascular networks
Age-related decrease in SVF-dependent neovascularization might be attributed to post-vasculogenic alterations, such as increased pruning during the remodeling or maturation phase of network formation. Therefore, we analyzed cell density and apoptosis in constructs explanted at two-weeks and four-weeks. Cell apoptosis does not differ between ySVF (N = 2) and oSVF (N = 5) at two weeks, but ySVF apoptosis significantly drops from 2.1 ± 0.3% at two weeks to 0.6 ± 0.2% at four weeks (N = 10) while oSVF apoptosis remains stable from 1.5 ± 0.6% to 1.7 ± 0.5% (N = 10; Fig. 3A) . Cell density is similar between ySVF (2541 cells/mm 2 , N = 2) and oSVF (2589 cells/mm 2 , N = 5) at two weeks, but a significant drop of 57.4% in cell density occurs with the oSVF at four weeks (1198 cells/mm 2 ) while ySVF at four weeks maintains its cell density (ySVF = 2735 cells/mm 2 , N = 10 per group; Fig. 3B ). This data shows that apoptosis and subsequent network pruning/remodeling decreases in ySVF implants between two and four weeks, but oSVF implants maintain high apoptotic rates which could contribute to the significant vascular pruning/remodeling observed by four weeks.
Antibody blocking effect of thrombospondin-1 on neovascularization
To determine whether the neovascularization deficit developed by oSVF relates to an increased contribution from Thbs-1-related inhibition of angiogenesis, we evaluated vascular network characteristics of oSVF constructs treated with Thbs-1 or control IgG antibody after two weeks in vivo. Total vessels and total perfused vessels were similar between groups (N ≥ 3; Fig. 4B, C) . However, antibody blockade of Thbs-1 improved the percent of perfused vascular volume in oSVF compared to oSVF + IgG (Fig. 4D) . Interestingly, vessel diameter distributions of oSVF with Thbs-1 antibody at two weeks resemble ySVF diameter distributions at four weeks (Fig. 1E) , suggesting that by blocking Thbs-1 the vascular network from oSVF is able to develop a more mature vascular network.
Discussion
Adipose-derived stromal vascular fraction cells exhibit the ability to form tube-like structures in vivo and support the accelerated formation of new microvascular structures when implanted in collagen gels. Studies were performed to explore how advanced age modifies the ability of adipose SVF to accelerate neovessel formation. The adipose SVF suspended in a collagen construct progresses through distinct phases Table 1 Selected genes from angiogenesis gene array (84 genes total) comparing primary isolation of ySVF to oSVF. Angiopoeitin-2 (Angpt2), chemokine (CXC motif) ligand 5 (CXCL5), granulin, hepatocyte growth factor (Hgf), platelet-derived growth factor beta polypeptide (PDGFβ), Thbs-1, tyrosine kinase with immunoglobin-like and EGF-like domains 1 (Tie1), tumor necrosis factor (Tnf) and VEGFA were all upregulated in oSVF compared to ySVF. Angiopoeitin-like 4 (Angptl4) and transforming growth factor beta 1 (Tgfβ1) were both negatively expressed in oSVF compared to ySVF. Fold regulation is the up-down regulation in old SVF compared to young SVF. Fold-regulation values greater than 2 are indicated in red, less than −2 are indicated in blue.
of neovascularization until explant four weeks later, most notably vasculogenesis/sprouting angiogenesis, inosculation, neovascular remodeling, and followed by vascular maturation (LeBlanc et al., 2012; Nunes et al., 2010 Nunes et al., , 2013 . The major findings support the conclusion that the aging process contributes to remarkably less complete vascular networks formed in vivo (Fig. 1) and a novel and somewhat surprising mechanism was uncovered. SVF from old rats exhibited comparable expression of an endothelial marker (CD31+) and yield of endothelial tubes formed in vitro when compared to ySVF ( Fig. 2B and Supplemental material). But follow-up experiments revealed that significant vascular regression (~50% less vessels, Fig. 1B , C) likely due to a sustained rate of apoptosis between two and four weeks in the oSVF implants (Fig. 3A) . This suggests that vasculogenic cells from old donors are not remiss in the ability to form vessels at the onset, but rather, the new vessels Fig. 3 . Time-dependent in vivo apoptosis in SVF constructs. TUNEL staining of SVF constructs revealed a decrease in apoptosis of young SVF from two to four weeks while levels of apoptosis remained elevated in old SVF (two weeks young n = 2, old n = 5; four weeks n = 10 both groups) (A). A corresponding reduction in cell density was noted in old SVF at four weeks (two weeks young n = 2, old n = 5; four weeks n = 10 per group) (B). *p b 0.05 notes differences between age groups, # p b 0.05 notes differences between time points within an age group. Fig. 4 . Perfused volume of vessels formed by old SVF is improved by thrombospondin-1 antibody incubation. Old SVF was treated with control IgG or thrombospondin-1 blocking antibody, suspended in collagen constructs, and implanted in Rag1 mice for two weeks. Perfused vessels were labeled with dextran-rhodamine and all vessels were labeled with GS-1-fluorescein (old + IgG ab n = 4, old + α-Thbs-1 n = 3). Representative images are shown (A). No differences were seen between groups in total or perfused vessel density (B, C). Treatment with α-Thbs-1 significantly increased the percent of vessel volume that was perfused (vol. perfused vessels / vol. total vessels × 100) (D). Analysis of the size distribution of vessels showed a shift towards a larger diameter in α-Thbs-1 treated SVF constructs (E). Scale bars are 100 μm, *p b 0.05.
formed are deficient in the ability to inosculate, mature and/or persist. By acutely blocking Thbs-1, a potent anti-angiogenic protein, we were able to increase the volume of perfused vessels formed and develop larger more mature vessels from oSVF. Importantly, the number of vessels formed was similar to constructs without Thbs-1 neutralizing antibody, which further supports the dysfunction with post-angiogenesis activities in oSVF. We believe that this is a novel and important finding because it implicates that therapies designed to grow new blood vessels in ischemic tissue should include a focus on improving the inosculation, remodeling and maturation phases of neovascularization in patients of advanced age (LeBlanc et al., 2012) .
Thbs-1, which can signal through cell surface receptor CD47, is a matricellular glycoprotein that plays a significant role in antiangiogenic processes through direct influence of endothelial cell migration and survival, and by indirect effects on mobilizing growth factors (Lawler, 2002) . Thbs-1 and CD47-null mice aged 14-18 months have previously shown superior ischemic tissue survival and improved vascular perfusion compared to age-matched controls hours after hindlimb ischemia, but this wasn't evaluated long-term (Isenberg et al., 2007) . Endothelial cells isolated from CD47-null mice have been shown to exhibit enhanced proliferation and decreased cellular senescence (Kaur et al., 2013) . Western blot analysis in the current study showed 1.91-fold higher expression of Thbs-1 protein in oSVF as compared to ySVF (Fig. 2C ), but flow cytometry showed a decrease in the number of cells brightly expressing CD47 in oSVF as compared to ySVF (69.3 +/− 2.8% v 82.6 +/− 1.9%, p b 0.05, Fig. 2B ). Since Thbs-1 signals through the cell surface receptor CD47, it would appear that these changes might counteract one another and prevent increased signaling through the Thbs-1/CD47 axis. However, it should be noted that while Thbs-1 protein levels are nearly doubled in oSVF, the corresponding decrease in number of CD47 ++ cells is more modest (0.16-fold decrease).
It is not likely that the decrease in CD47 ++ cells is large enough to balance the substantial increase in Thbs-1 expression that was observed. Another important consideration is that Thbs-1 has many known ligands besides CD47. Binding of the CD36 receptor on endothelial cells by Thbs-1 has been shown to inhibit neovascularization in vitro and in vivo (Dawson et al., 1997; Jimenez et al., 2000) . A possible role of Thbs-1/CD36 signaling in the reduced neovascular potential of oSVF is an area for future study. A recent study found that age-associated capillary rarefaction in mice could be abrogated by disrupting Thbs-1, which in turn attenuated the upregulation of angiopoietin-2 (Ang-2) (Gonzalez-Quesada et al., 2013) , another mediator of vascular regression. We show in the present study that Thbs-1 and Ang-2 are both upregulated in oSVF compared to ySVF (Table 1, Fig. 2C ). Since oSVF retains the ability to assemble and form vascular networks comparable in number to ySVF, but undergoes significant rarefaction once these vessels become patent, it is likely that Thbs-1 signaling is involved. Antibody blocking of Thbs-1 improved the volume of perfused vessels created in oSVF constructs and promoted the growth and persistence of larger diameter vessels at two weeks. This suggests that a chronic blockade of Thbs-1 may be able to interrupt the later stages of neovascularization between two and four weeks, when vascular remodeling/rarefaction and maturation primarily dominate neovascularization activities. These results identify a potential mechanism by which suppressing Thbs-1 may retard the potent rarefaction and anti-angiogenic effects observed in old SVF and lead to vascular maturation and improved neovascularization.
Another plausible mechanism by which aging and Thbs-1 may play a role in SVF vascular network formation is at earlier time points in the neovascularization process, notably vessel sprouting/formation and inosculation. Almost 20 years ago, Thbs-1 was shown to inhibit the transition from a resting to a sprouting phenotype in endothelial cells (Canfield and Schor, 1995) , giving credence to an "angiogenic switch" that can be turned on or off in certain systems. Subsequently, Thbs-1 was found to induce apoptosis of endothelial cells in vitro and in vivo (Jimenez et al., 2000) . Theoretically, an age-dependent increase in Thbs-1 protein in oSVF constructs at the time of implantation may be causing early apoptosis of new vessels, hindering eventual network formation. However, this is unlikely due to the fact that oSVF constructs treated with Thbs-1 neutralizing antibody demonstrate similar number of vessels formed after two weeks when compared to control antibody constructs (Fig. 4) , and this is confirmed by our in vitro results (Supplementary data). This suggests that there is no Thbs-1-related decrement in the angiogenesis phase of in vivo neovascularization of SVF from aged animals. Further, Thbs-1 protein was undetectable in two-and four-week constructs made from oSVF (data not shown). This supports the strong possibility that there might be age-dependent differences in the inosculation phase, independent of Thbs-1 contribution, but more experiments are needed to explore this time point of neovascularization.
The microarray analysis shown in Table 1 reveals up-regulation of several genes in oSVF that may influence its neovascular and inflammatory activity. The ELR + CXC motif chemokine CXCL5 (30.9-fold increase) is a potent neutrophil chemoattractant and has been shown to play a role in tumor angiogenesis (White et al., 2003) . Aptly, our flow cytometry results show increased presence of cells expressing the ELR+ chemokine receptor CXCR2, which could possibly indicate an increased neutrophil presence in oSVF. Granulin (17.3-fold increase) mediates both pro-inflammatory and anti-inflammatory responses depending on cleavage state and the local environment (Jian et al., 2013) . The uncleaved protein, known as progranulin, has been shown to inhibit inflammatory signaling through the TNF pathway, but cleavage by neutrophil-derived elastase forms the pro-inflammatory molecule granulin (Jian et al., 2013) . It is possible that CXCL5 drives the cleavage of progranulin to granulin by increasing neutrophil presence, pushing the cytokine network balance towards a pro-inflammatory state. Further evidence of increased inflammatory status in oSVF is revealed by the increased expression of TNF (3.4-fold increase). TNF is known to activate caspases that result in apoptosis as well as the pro-inflammatory transcription factors AP-1 and NF-κB (Baud and Karin, 2001) , the latter of which has been shown to mediate agerelated endothelial dysfunction (Donato et al., 2009) . Increased expression of these inflammatory markers in oSVF may be a consequence of age-related low-grade systemic or vascular inflammation in the donor animals (Franceschi et al., 2007) . Since the therapeutic potential of SVF and other MSC populations in ischemic disease, transplantation, and other applications is mediated in large part by immunomodulation and promotion of tissue integrity, an age-related change in the inflammatory status of SVF is of primary concern to translational studies.
It is commonly believed that aging results in a tissue environment that is not conducive to promoting the growth of new vessels and maintaining them past the initial angiogenic phase. For example, stimulating angiogenesis in an old mouse through implanting collagen constructs embedded with growth factor results in decreased capillary ingrowth compared to those implanted in young mice (Swift et al., 1999) . Coparabiotic studies have suggested that circulating factors contribute to the poor recovery from injury and angiogenic dysfunction observed in aged animals (Conboy et al., 2013; Pietramaggiori et al., 2009 ) and heterochronic parabiotic pairings have shown an improvement in the function of resident progenitor cells of the aged animal (Conboy and Rando, 2012) . Therefore, the presence of one or more "young" circulating factors may be critical to improve angiogenesis and injury repair in the aged environment. However, a recent study contradicts this theory. De Barros et al. (2013) showed that implanting human ADSCs from donors (aged over 50 years) into a young mouse model of hindlimb ischemia did not improve cutaneous blood flow compared to younger donors (20-35 years) (De Barros et al., 2013) . This suggests that a young environment may not be able to fully overcome innate age-related changes in angiogenic function in cells from old donors, despite potential beneficial circulating factors from young hosts. The present study supports this, as SVF from old donors was unable to achieve neovascularization to a level similar to young SVF even though it was implanted in a young host (Fig. 1) .
It is also essential to consider whether implanting young SVF or old SVF in an old host would result in even more inferior vascular growth than demonstrated in the present study due to "old", potentially deleterious circulating factors. This is because the cohort most commonly afflicted with ischemia, and needing subsequent vascular therapies, is the aged population. Host/recipient age-related comparisons have been completed utilizing BMSCs in a mouse model of hindlimb ischemia. By varying donor cell age/recipient host age, Zhuo et al. (2010) reported young/young as achieving the highest arteriolar and capillary density, followed by similar results between young/old and old/young, and finally marking old/old as the fewest vessels formed following injury and cell treatment (Zhuo et al., 2010) . Therefore, not only do the isolated cells from old donors retain age-related neovascularization dysfunction, but also the extent of vascular regeneration potentially could be even less if implanted in the aged population. This is especially important to discern in future studies because of the clinical relevance of autologous cell-based therapies.
The current paradigm is that regenerative cells act primarily through paracrine mechanisms (e.g. production of angiogenic factors) to induce neovascularization, tissue repair, and evoke responses from resident cells (Baraniak and McDevitt, 2010; Duran et al., 2013; Gnecchi et al., 2008; Hatzistergos et al., 2010) . When implanted in conjunction with a growth factor (FGF2) into an ischemic tissue environment, ADSCs produce even more growth factors (VEGF, HGF, FGF2) and result in improved survival and blood perfusion in young donors and hosts (Bhang et al., 2009 ). In 2011, Koh et al. implanted SVF in matrigel supplemented with both VEGF-A and angiopoietin-1 (Ang1) and reported 9.7-fold increase in vascular perfusion after two weeks compared to SVF alone (Koh et al., 2011 ), but did not evaluate if this effect persisted during later stages of neovascularization. Although the present study did not supplement with growth factors in vivo, our study did show that conditioned media collected from young SVF did not improve angiogenic characteristics of oSVF in vitro (Supplemental material). It's possible that the addition of 2-3 growth factors could improve angiogenesis in vivo, but it's more likely that the acute incubation of the oSVF constructs with embedded growth factors would only improve initial vessel density (0-2 weeks) and would not persist long enough to participate in the vascular remodeling and maturation phases.
SVF is a relatively easy cell source to obtain but is frequently subselected and extensively cultured to obtain expanded, specific cell populations (i.e. ADSCs, CD34 + /CD133 + , c-kit + , etc.). Cultured SVF from old mice demonstrated lower VEGF production, proliferation and tubulogenesis compared to SVF from young mice (El-Ftesi et al., 2009) . Recently, a subpopulation (CD45−/CD34+/CD133+) isolated from the adipose tissue of elderly humans showed decreased angiogenic potential of progenitor cells, as measured by in vitro tube/network formation, compared to young, healthy counterparts (Madonna et al., 2011) . Other studies have gone on to demonstrate that adiposederived cells from older patients exhibit shorter telomeres, reduced telomerase activity (Madonna et al., 2013) and less angiogenic factor production (De Barros et al., 2013; Efimenko et al., 2014) . The present study is unique in that it utilizes the entire SVF population from an established aging model and employed no culturing, passaging, and sub-selection to evaluate in vivo neovascularization potential; all in an effort to more closely resemble future autologous clinical applications where SVF can be isolated and implanted almost simultaneously. Further, this study is the first to examine the relationship between Thbs-1, adipose-derived SVF and neovascularization in advancing age. The results of this study emphasize the need to further examine post-angiogenesis phases of neovascularization for the development of future ischemic therapies, but some limitations of the present study should be considered.
Limitations of the study, future studies
In this study we observed an age-related reduction in the neovascular potential of adipose SVF. These studies are based on a single dose of cells and future studies will need to establish the dose dependency of adipose SVF cell therapies to support new blood vessel formation. To better understand the vascular remodeling events responsible for this decline, explant of vascular constructs at additional time points (at inosculation and between two and four weeks) or the use of a skin fold window model for real time visualization would be needed. The mechanisms underlying the reduction in neovascular potential with age are not fully established, however, our results strongly support that aging-induced changes in Thbs-1 expression may contribute. The complex nature of the interaction between chemokines, inflammation, and angiogenesis requires many subsequent studies to identify the mechanisms by which increases in CXCL5/CXCR2 or Thbs-1/CD36 signaling may possibly influence neovascularization. The aging process may also change the relative distribution of different cell types in the heterogeneous SVF cell population as well as the ability of cells to synthesize and excrete paracrine factors. This study used an in vivo model of neovascularization using a collagen construct implanted in healthy Rag1 mice. The site of implantation, the disease state of the recipient and the age of the recipient may also have an effect on the neovascularization process.
Conclusion
This study evaluated the effects of aging on the ability of adipose derived stromal vascular fraction cells to support accelerated neovascularization. There is an age-dependent impairment in the formation of functional microvascular networks following implantation of adipose SVF cell containing collagen constructs. Thrombospondin-1 plays a role in the observed reduction in neovascularization using adipose SVF from old animals. These results have direct implications for future autologous therapies designed for treating ischemic disease in the elderly.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.exger.2015.01.044.
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